Teladoc, Inc. (TDOC) Receives Consensus Rating of “Buy” from Analysts
Teladoc, Inc. (NYSE:TDOC) has been assigned an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $37.30.
A number of equities research analysts recently commented on TDOC shares. Canaccord Genuity reissued a “buy” rating and issued a $34.00 price objective on shares of Teladoc in a research note on Wednesday, May 24th. Chardan Capital increased their price objective on shares of Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, June 20th. Robert W. Baird reissued a “buy” rating and issued a $28.00 price objective on shares of Teladoc in a research note on Tuesday, May 9th. Piper Jaffray Companies reissued a “buy” rating and issued a $32.00 price objective on shares of Teladoc in a research note on Friday, July 14th. Finally, TheStreet cut shares of Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd.
Teladoc (NYSE:TDOC) opened at 30.35 on Friday. Teladoc has a 12-month low of $14.00 and a 12-month high of $36.90. The firm’s 50-day moving average is $33.88 and its 200 day moving average is $27.52. The stock’s market capitalization is $1.72 billion.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same period last year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 68.3% compared to the same quarter last year. Equities analysts expect that Teladoc will post ($1.47) EPS for the current year.
In other news, CEO Jason N. Gorevic sold 14,400 shares of the stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $29.57, for a total transaction of $425,808.00. Following the transaction, the chief executive officer now directly owns 822,961 shares in the company, valued at approximately $24,334,956.77. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 5,600 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $29.57, for a total transaction of $165,592.00. Following the transaction, the chief executive officer now owns 823,861 shares in the company, valued at $24,361,569.77. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 207,186 shares of company stock worth $6,122,950. Insiders own 5.94% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its stake in Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock worth $6,309,000 after buying an additional 9,146 shares during the period. Teachers Advisors LLC increased its stake in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock worth $581,000 after buying an additional 1,759 shares during the period. First Mercantile Trust Co. acquired a new stake in Teladoc during the first quarter worth about $175,000. Russell Investments Group Ltd. acquired a new stake in Teladoc during the first quarter worth about $583,000. Finally, Wells Fargo & Company MN increased its stake in Teladoc by 43.8% in the first quarter. Wells Fargo & Company MN now owns 543,568 shares of the health services provider’s stock worth $13,589,000 after buying an additional 165,435 shares during the period. Institutional investors and hedge funds own 95.88% of the company’s stock.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.